Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 1, 2005, Pages 21-23

  Tyagi, Preeta ^a   Chu, Edward ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG POTENTIATION; FATIGUE; HUMAN; INJECTION SITE REACTION; METASTASIS POTENTIAL; NAUSEA; NONHUMAN; SOLID TUMOR; TREATMENT FAILURE; VOMITING; COLORECTAL TUMOR; DRUG RESISTANCE; IMMUNOLOGY; METASTASIS; PATHOLOGY; REVIEW; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 21844438498     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70161-X     Document Type: Article

References (11)

1. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29(suppl 14):38-44.
2. Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-1243.
3. Brüggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-1361.
4. Figlin RA, Belldegrun A, Crawford J, et al. Panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 2002; 21: 10a (Abstract #35).
5. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3511).
6. Hecht JR, Berlin J, Malik I, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in metastatic colorectal cancer (mCRC) patients: a pharmacokinetic (PK) analysis. Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL (Abstract #259).
7. Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2004; 15(suppl 3):70 (Abstract #265PD).
8. Abgenix announces ABX-EGF enters pivotal trial in advanced colorectal cancer patients [press release]. Fremont, CA: Abgenix, Inc.; January 20, 2004.
9. Saltz L, Lenz H, Kindler HL, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/ bevacizumab (CB) in colorectal cancer. Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, January 27-29, 2005; Hollywood, FL (Abstract #169b).
10. Safety of AMG 706 plus panitumumab plus chemotherapy in the treatment of subjects with metastatic colorectal cancer. National Institutes of Health [Web site]. Available at: http://www.clinicaltrials.gov/ct/show/NCT00101894?order=1. Accessed February 14, 2005.
11. FDA grants fast track designation for Amgen's AMG 531 and AMG 706 experimental therapies to potentially treat life-threatening conditions [press release]. Thousand Oaks, CA: Amgen Inc; December 6, 2004.